Clinical observation on the application of Jianpi Yichang powder based on the theory of "regulating the middle and restoring balance" to prevent postoperative recurrence of spleen deficiency type intestinal polyps

注册号:

Registration number:

ITMCTR2024000347

最近更新日期:

Date of Last Refreshed on:

2024-09-01

注册时间:

Date of Registration:

2024-09-01

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

基于“调中复衡”理论应用健脾益肠散预防脾虚型肠息肉术后复发的临床观察

Public title:

Clinical observation on the application of Jianpi Yichang powder based on the theory of "regulating the middle and restoring balance" to prevent postoperative recurrence of spleen deficiency type intestinal polyps

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于“调中复衡”理论应用健脾益肠散预防脾虚型肠息肉术后复发的临床观察

Scientific title:

Clinical observation on the application of Jianpi Yichang powder based on the theory of "regulating the middle and restoring balance" to prevent postoperative recurrence of spleen deficiency type intestinal polyps

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王哲

研究负责人:

王哲

Applicant:

Wang Zhe

Study leader:

Wang Zhe

申请注册联系人电话:

Applicant telephone:

+86 158 0451 4492

研究负责人电话:

Study leader's telephone:

+86 158 0451 4492

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

cjwdwz@126.com

研究负责人电子邮件:

Study leader's E-mail:

cjwdwz@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

中国黑龙江省哈尔滨市香坊区湘江路2号

研究负责人通讯地址:

中国黑龙江省哈尔滨市香坊区湘江路2号

Applicant address:

No2,xiangjiang road,xiangfang district,Harbin city,heilongjiang province,China mainland

Study leader's address:

No2,xiangjiang road,xiangfang district,Harbin city,heilongjiang province,China mainland

申请注册联系人邮政编码:

Applicant postcode:

150036

研究负责人邮政编码:

Study leader's postcode:

150036

申请人所在单位:

黑龙江中医药大学附属第三医院

Applicant's institution:

Third Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2023002

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

黑龙江中医药大学附属第三医院伦理委员会

Name of the ethic committee:

Ethics Committee of the Third Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2023/4/11 0:00:00

伦理委员会联系人:

于天一

Contact Name of the ethic committee:

Yu Tianyi

伦理委员会联系地址:

中国黑龙江省哈尔滨市香坊区湘江路2号

Contact Address of the ethic committee:

No2,xiangjiang road,xiangfang district,Harbin city,heilongjiang province,China mainland

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 451 5110 8047

伦理委员会联系人邮箱:

Contact email of the ethic committee:

zydsy8888@163.com

研究实施负责(组长)单位:

黑龙江中医药大学附属第三医院

Primary sponsor:

Third Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

中国黑龙江省哈尔滨市香坊区湘江路2号

Primary sponsor's address:

No2,xiangjiang road,xiangfang district,Harbin city,heilongjiang province,China mainland

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

黑龙江

市(区县):

哈尔滨

Country:

China

Province:

Heilongjiang

City:

Harbin

单位(医院):

黑龙江中医药大学附属第三医院

具体地址:

中国黑龙江省哈尔滨市香坊区湘江路2号

Institution
hospital:

Third Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine

Address:

No2,xiangjiang road,xiangfang district,Harbin city,heilongjiang province,China mainland

经费或物资来源:

自筹经费

Source(s) of funding:

Self-financing

研究疾病:

结肠息肉

研究疾病代码:

Target disease:

Colonic polyps

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

非随机对照试验

Non randomized control

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

结肠息肉是临床常见病、多发病,目前内镜下切除已经取得很好的疗效,但此病具有反复发作特点,如何有效地预防复发,已成为目前临床工作中有待解决的问题。 1.基于“调中复衡”理论为指导的中药配方(健脾益肠散)在预防肠息肉术后复发的临床价值有待我们进一步证实。 2.在传统医学和现代医学上关于结肠息肉术后复发的病因机制均尚未完成阐明,本研究基于“调中复衡”理论应用健脾益肠散治疗的方法,以探讨对脾虚型结肠息肉术后复发的预防作用。

Objectives of Study:

Colon polyps are a common and frequently occurring disease in clinical practice. Currently, endoscopic resection has achieved good results, but this disease has the characteristic of recurrent episodes. How to effectively prevent recurrence has become a problem that needs to be solved in clinical work. The clinical value of the traditional Chinese medicine formula (Jianpi Yichang San) guided by the theory of "regulating the middle and restoring balance" in preventing postoperative recurrence of intestinal polyps needs further confirmation from us. 2. The etiology and mechanism of postoperative recurrence of colon polyps have not been fully elucidated in both traditional and modern medicine. This study is based on the theory of "regulating the middle and restoring balance" and applies the method of Jianpi Yichang San to explore the preventive effect on postoperative recurrence of spleen deficiency type colon polyps.

药物成份或治疗方案详述:

黄芪、太子参、茯苓、焦白术、芡实、木香、白豆蔻、补骨脂、甘草 将饮片打粉制成散剂,2次/d,温水送服,共7剂为一个疗程。共三个疗程

Description for medicine or protocol of treatment in detail:

Huangqi Taizishen Fuling Jiaobaizhu Euryale Muxiang Cardamom Psoralea Licorice Powder the decoction pieces into a powder twice a day and take them with warm water. A total of 7 doses constitute one course of treatment. Three treatment courses in total.

纳入标准:

1.符合西医内镜诊断标准及中医证候诊断标准; 2.入组时肠息肉病理诊断为腺瘤,年龄18-80岁,性别不限; 3.神志清楚,可配合治疗; 4.无严重心肺等内科疾病; 5.同意参加临床研究,并签署知情同意书

Inclusion criteria

1. Meet the diagnostic criteria of Western endoscopy and traditional Chinese medicine syndrome diagnosis; At the time of enrollment the pathological diagnosis of intestinal polyps was adenoma with an age range of 18-80 years and no gender limitation; 3. Clear consciousness can cooperate with treatment; 4. No serious internal medicine diseases such as cardiovascular and pulmonary diseases; 5. Agree to participate in clinical research and sign an informed consent form.

排除标准:

(1)家族性息肉病、炎症性肠病;P-J综合征 (2)结/直肠癌; (3)合并严重的心脑血管、肺、肝、肾和造血系统等严重原发性疾病的患者; (4)对本药过敏者; (5)精神状态异常者; (6)正在参加其他临床受试者。

Exclusion criteria:

(1) Familial polyposis and inflammatory bowel disease; P-J syndrome (2) Colorectal cancer; (3) Patients with severe primary diseases such as cardiovascular, cerebrovascular, pulmonary, hepatic, renal, and hematopoietic systems; (4) Individuals who are allergic to this medication; (5) Individuals with abnormal mental states; (6) Participating in other clinical trials.

研究实施时间:

Study execute time:

From 2024-01-01

To      2025-12-31

征募观察对象时间:

Recruiting time:

From 2024-01-01

To      2025-12-31

干预措施:

Interventions:

组别:

观察组

样本量:

30

Group:

observation group

Sample size:

干预措施:

不进行药物干预,常规复查评估

干预措施代码:

Intervention:

No medication intervention, routine follow-up evaluation

Intervention code:

组别:

试验组

样本量:

30

Group:

Test group

Sample size:

干预措施:

试验组给予自拟中药“健脾益肠散”口服,2次/d,温水送服,7天为一个疗程。共三个疗程,连续21日。

干预措施代码:

Intervention:

The experimental group was given a self formulated traditional Chinese medicine "Jianpi Yichang San" orally, twice a day, with warm water for 7 days as one course of treatment. There are three treatment courses in total, lasting for 21 consecutive days.

Intervention code:

样本总量 Total sample size : 60

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

黑龙江

市(区县):

哈尔滨

Country:

China

Province:

Heilongjiang

City:

Harbin

单位(医院):

黑龙江中医药大学附属第三医院

单位级别:

三级

Institution/hospital:

Third Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

息肉的病理组织学分型

指标类型:

附加指标

Outcome:

Histopathological classification of polyps

Type:

Additional indicator

测量时间点:

6-12个月

测量方法:

病理检查

Measure time point of outcome:

6-12 months

Measure method:

pathological examination

指标中文名:

腺瘤复发率

指标类型:

主要指标

Outcome:

Adenoma recurrence rate

Type:

Primary indicator

测量时间点:

6-12个月

测量方法:

肠镜复查结果

Measure time point of outcome:

6-12 months

Measure method:

Colonoscopy review results

指标中文名:

中医证候评分量表

指标类型:

次要指标

Outcome:

Traditional Chinese Medicine Syndrome Rating Scale

Type:

Secondary indicator

测量时间点:

6-12个月

测量方法:

调查问卷

Measure time point of outcome:

6-12 months

Measure method:

questionnaire

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织切片

组织:

大肠

Sample Name:

tissue section

Tissue:

colon

人体标本去向

其它

说明

Fate of sample 

Others

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

由患者自主决定是否应用药物观察方案,而后医生对于两组组别患者进行分组观察。

Randomization Procedure (please state who generates the random number sequence and by what method):

NONE

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

-

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

-

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

-

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

-

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above